1. Home
  2. MGIC vs CMMB Comparison

MGIC vs CMMB Comparison

Compare MGIC & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGIC
  • CMMB
  • Stock Information
  • Founded
  • MGIC 1983
  • CMMB 2004
  • Country
  • MGIC Israel
  • CMMB Israel
  • Employees
  • MGIC N/A
  • CMMB N/A
  • Industry
  • MGIC Computer Software: Prepackaged Software
  • CMMB Biotechnology: Pharmaceutical Preparations
  • Sector
  • MGIC Technology
  • CMMB Health Care
  • Exchange
  • MGIC Nasdaq
  • CMMB Nasdaq
  • Market Cap
  • MGIC N/A
  • CMMB 37.3M
  • IPO Year
  • MGIC 1991
  • CMMB N/A
  • Fundamental
  • Price
  • MGIC $12.81
  • CMMB $1.98
  • Analyst Decision
  • MGIC Buy
  • CMMB Strong Buy
  • Analyst Count
  • MGIC 1
  • CMMB 2
  • Target Price
  • MGIC $15.00
  • CMMB $7.50
  • AVG Volume (30 Days)
  • MGIC 46.7K
  • CMMB 77.2K
  • Earning Date
  • MGIC 03-12-2025
  • CMMB 03-06-2025
  • Dividend Yield
  • MGIC 3.42%
  • CMMB N/A
  • EPS Growth
  • MGIC N/A
  • CMMB N/A
  • EPS
  • MGIC 0.70
  • CMMB N/A
  • Revenue
  • MGIC $535,482,999.00
  • CMMB N/A
  • Revenue This Year
  • MGIC $4.29
  • CMMB N/A
  • Revenue Next Year
  • MGIC $3.39
  • CMMB N/A
  • P/E Ratio
  • MGIC $18.38
  • CMMB N/A
  • Revenue Growth
  • MGIC N/A
  • CMMB N/A
  • 52 Week Low
  • MGIC $9.51
  • CMMB $0.55
  • 52 Week High
  • MGIC $13.46
  • CMMB $2.55
  • Technical
  • Relative Strength Index (RSI)
  • MGIC 52.98
  • CMMB 47.93
  • Support Level
  • MGIC $12.94
  • CMMB $1.86
  • Resistance Level
  • MGIC $13.35
  • CMMB $2.15
  • Average True Range (ATR)
  • MGIC 0.28
  • CMMB 0.14
  • MACD
  • MGIC -0.02
  • CMMB -0.02
  • Stochastic Oscillator
  • MGIC 39.25
  • CMMB 36.36

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Share on Social Networks: